Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
PRTA's Cash to Debt is ranked higher than
80% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. PRTA: No Debt )
PRTA' s 10-Year Cash to Debt Range
Min: N/A   Max: No Debt
Current: No Debt


Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6421
N/A
No Debt
Equity to Asset 0.96
PRTA's Equity to Asset is ranked higher than
98% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. PRTA: 0.96 )
PRTA' s 10-Year Equity to Asset Range
Min: 0.91   Max: 0.98
Current: 0.96

0.91
0.98
Interest Coverage No Debt
PRTA's Interest Coverage is ranked higher than
98% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PRTA: No Debt )
PRTA' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 48.29
M-Score: -2.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -206.62
PRTA's Operating margin (%) is ranked higher than
66% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. PRTA: -206.62 )
PRTA' s 10-Year Operating margin (%) Range
Min: -5980.33   Max: -13.07
Current: -206.62

-5980.33
-13.07
Net-margin (%) -209.25
PRTA's Net-margin (%) is ranked higher than
66% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. PRTA: -209.25 )
PRTA' s 10-Year Net-margin (%) Range
Min: -6064.5   Max: -14.06
Current: -209.25

-6064.5
-14.06
ROE (%) -14.78
PRTA's ROE (%) is ranked higher than
78% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. PRTA: -14.78 )
PRTA' s 10-Year ROE (%) Range
Min: -68.99   Max: -3.09
Current: -14.78

-68.99
-3.09
ROA (%) -14.13
PRTA's ROA (%) is ranked higher than
77% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. PRTA: -14.13 )
PRTA' s 10-Year ROA (%) Range
Min: -1640.13   Max: -2.94
Current: -14.13

-1640.13
-2.94
ROC (Joel Greenblatt) (%) -1245.83
PRTA's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. PRTA: -1245.83 )
PRTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2303.58   Max: -204.81
Current: -1245.83

-2303.58
-204.81
» PRTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

PRTA Guru Trades in Q2 2014

Paul Tudor Jones 30,549 sh (New)
Leon Cooperman 100,000 sh (New)
Vanguard Health Care Fund 1,662,794 sh (+25.26%)
Jim Simons 51,900 sh (-34.40%)
» More
Q3 2014

PRTA Guru Trades in Q3 2014

Vanguard Health Care Fund 1,662,794 sh (unchged)
Paul Tudor Jones Sold Out
Leon Cooperman 80,000 sh (-20.00%)
Jim Simons 17,300 sh (-66.67%)
» More
Q4 2014

PRTA Guru Trades in Q4 2014

Vanguard Health Care Fund 1,662,794 sh (unchged)
Leon Cooperman Sold Out
Jim Simons Sold Out
» More
Q1 2015

PRTA Guru Trades in Q1 2015

Vanguard Health Care Fund 1,662,794 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PRTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.30
PRTA's P/B is ranked higher than
81% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. PRTA: 3.30 )
PRTA' s 10-Year P/B Range
Min: 0.84   Max: 5.16
Current: 3.3

0.84
5.16
P/S 46.16
PRTA's P/S is ranked higher than
53% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. PRTA: 46.16 )
PRTA' s 10-Year P/S Range
Min: 8.29   Max: 900.25
Current: 46.16

8.29
900.25
EV-to-EBIT -17.38
PRTA's EV-to-EBIT is ranked higher than
58% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PRTA: -17.38 )
PRTA' s 10-Year EV-to-EBIT Range
Min: -348.9   Max: 0.9
Current: -17.38

-348.9
0.9
Current Ratio 29.80
PRTA's Current Ratio is ranked higher than
97% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. PRTA: 29.80 )
PRTA' s 10-Year Current Ratio Range
Min: 12.51   Max: 72.16
Current: 29.8

12.51
72.16
Quick Ratio 29.80
PRTA's Quick Ratio is ranked higher than
97% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. PRTA: 29.80 )
PRTA' s 10-Year Quick Ratio Range
Min: 12.51   Max: 72.16
Current: 29.8

12.51
72.16
Days Sales Outstanding 25.78
PRTA's Days Sales Outstanding is ranked higher than
94% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. PRTA: 25.78 )
PRTA' s 10-Year Days Sales Outstanding Range
Min: 12.41   Max: 31.32
Current: 25.78

12.41
31.32

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.50
PRTA's Price/Net Cash is ranked higher than
94% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 220.30 vs. PRTA: 3.50 )
PRTA' s 10-Year Price/Net Cash Range
Min: 1.05   Max: 4.56
Current: 3.5

1.05
4.56
Price/Net Current Asset Value 3.50
PRTA's Price/Net Current Asset Value is ranked higher than
93% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. PRTA: 3.50 )
PRTA' s 10-Year Price/Net Current Asset Value Range
Min: 1.03   Max: 4.44
Current: 3.5

1.03
4.44
Price/Tangible Book 3.40
PRTA's Price/Tangible Book is ranked higher than
86% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. PRTA: 3.40 )
PRTA' s 10-Year Price/Tangible Book Range
Min: 1   Max: 4.35
Current: 3.4

1
4.35
Price/Median PS Value 1.20
PRTA's Price/Median PS Value is ranked higher than
97% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. PRTA: 1.20 )
PRTA' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 18.29
Current: 1.2

0.26
18.29
Earnings Yield (Greenblatt) -5.30
PRTA's Earnings Yield (Greenblatt) is ranked higher than
68% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. PRTA: -5.30 )
PRTA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -5.6   Max: 74709.2
Current: -5.3

-5.6
74709.2

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0PT.Germany,
Prothena Corporation PLC was incorporated in Ireland as a private limited company under the name Neotope Corporation Limited on September 26, 2012. On November1, 2012, it changed the name of the company to Prothena Corporation plc. It is a biotechnology company engaged in the discovery and development of novel antibodies for the potential treatment of an array of diseases that involve protein misfolding or cell adhesion. Its research and development pipeline includes three main therapeutic antibody programs: NEOD001 for the treatment of AL and AA Amyloidosis; PRX002 (formerly NEOD002) for the treatment of Parkinson's disease; and PRX003 for the potential treatment of inflammatory disease and metastatic cancers. Its pipeline also includes two late discovery stage programs: tau antibodies for potential treatment of Alzheimer's disease and antibodies for the potential treatment of type 2 diabetes. The competitors consist of major international companies, all of which are larger and have greater financial resources, technical staff, manufacturing, R&D and marketing capabilities. It also competes with smaller research companies and generic drug and biosimilar manufacturers. It is subject to significant regulation by international, national, state and local governmental regulatory agencies.
» More Articles for PRTA

Headlines

Articles On GuruFocus.com
Prothena (PRTA) Potential Parkinson's Treatment, Envivio (ENVI) Improved Results, Nike (NKE) Profita Mar 20 2015 
Three Stocks With Massive Insider Buying Sep 03 2014 

More From Other Websites
PROTHENA CORP PLC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 22 2015
Prothena Announces Presentation of Clinical Data From the Ongoing Phase 1/2 NEOD001 Study and... May 21 2015
Prothena Announces Presentation of Clinical Data From the Ongoing Phase 1/2 NEOD001 Study and... May 21 2015
Prothena Announces Presentation of Clinical Data From the Ongoing Phase 1/2 NEOD001 Study and... May 21 2015
Prothena to Present Updated Clinical Data From Ongoing Phase 1/2 Study of NEOD001 at 2015 ASCO... May 13 2015
Prothena to Present Updated Clinical Data From Ongoing Phase 1/2 Study of NEOD001 at 2015 ASCO... May 13 2015
Prothena to Present Updated Clinical Data From Ongoing Phase 1/2 Study of NEOD001 at 2015 ASCO... May 13 2015
PROTHENA CORP PLC Financials May 13 2015
Credit Suisse Analysts Assume Coverage On 10 Biotech Stocks May 06 2015
Prothena (PRTA) Posts Narrower-than-Expected Loss in Q1 - Analyst Blog May 06 2015
PROTHENA CORP PLC Files SEC form 10-Q, Quarterly Report May 06 2015
Prothena reports 1Q loss May 05 2015
Prothena reports 1Q loss May 05 2015
Prothena Reports First Quarter 2015 Financial Results and Provides R&D Update May 05 2015
Prothena Reports First Quarter 2015 Financial Results and Provides R&D Update May 05 2015
PROTHENA CORP PLC Files SEC form 8-K, Results of Operations and Financial Condition May 05 2015
Prothena Reports First Quarter 2015 Financial Results and Provides R&D Update May 05 2015
The Michael J. Fox Foundation and Prothena Partner to Accelerate Discovery of Novel Biomarkers for... May 04 2015
The Michael J. Fox Foundation and Prothena Partner to Accelerate Discovery of Novel Biomarkers for... May 04 2015
The Michael J. Fox Foundation and Prothena Partner to Accelerate Discovery of Novel Biomarkers for... May 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK